Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice.
Most drug discovery efforts for Alzheimer's disease (AD) have focused on prevention or clearance of beta-amyloid (Abeta) fibrils or oligomers, with far less attention to prevention of tau abnormalities that lead to neurofibrillary tangles (NFTs). Much evidence now indicates that Abeta multimers can trigger neurodegenerative changes that involve formation of dystrophic neurites and cytoskeletal collapse, possibly due loss of microtubule (MT) stabilization by the tau protein. We have found that several MT-stabilizing agents such as Taxol significantly enhanced neuronal survival in the presence of Abeta and identified agents that enter the brain, a necessity for in vivo testing in animal models of tau pathology. Studies were designed to test two agents in the tau mutant (JNPL3) mouse that develops severe motor deficits at about seven months of age, accompanied by neuropathological markers of tau pathology. In addition to using motor performance tests through the planned period of drug administration, we designed a simple appetitive memory test that required a reduction in ad lib food intake. Although the neurochemical data are still being analyzed, we were surprised to find that all of the JNPL3 mice, whether receiving the drug or not, developed no signs of motor impairment up to 10 months of age. This is considerably beyond the age at which free-fed mice survived and suggests that the food restriction alone may have delayed the pathological process. A study is ongoing with free-fed mice to determine if the drug interventions do have any beneficial effects in these mutant mice.
Michaelis
Mary L
ML
Department of Pharmacology & Toxicology, School of Pharmacy, University of Kansas, 1241 Wescoe Hall Dr., Lawrence, KS 66045, USA. mlm@ku.edu
Georg
G
G
Telikepalli
H
H
McIntosh
M
M
Rajewski
R A
RA
D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D001245:Association Learning / Q000187:drug effects; D001812:Blood-Brain Barrier / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D031204:Caloric Restriction; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D051379:Mice; D008822:Mice, Transgenic; D008870:Microtubules / Q000187:drug effects*; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology*; D012054:Reinforcement, Psychology; D045442:Rotarod Performance Test; D016875:tau Proteins / Q000187:drug effects*
C497149:10-O-deacetylpaclitaxel 10-monosuccinyl ester; D016875:tau Proteins; D017239:Paclitaxel